Skip to main content

Oxford BioMedica

Oxford Biomedica plc is a British cell and gene therapy Contract Development and Manufacturing Organization (CDMO) delivering viral vector bioprocessing solutions. The company develops and manufactures lentiviral and adeno-associated virus (AAV) vectors utilized in cell and gene therapy treatments using its LentiVector platform. Main revenue drivers consist of bioprocessing manufacturing fees, cell therapy contract development retainers, and commercial licensing royalties billed to pharmaceutical clients. Oxford Biomedica serves global biopharmaceutical corporations, biotechnology developers, and clinical trial sponsors across Europe, North America, and Asia. The company holds a market-leading global position as a premier specialized CDMO for lentiviral and AAV gene therapy vectors. Headquartered in Oxford, United Kingdom, Oxford Biomedica plc is listed on the London Stock Exchange.

2 of the funds FundTelligence covers report a position in Oxford BioMedica.

Legal name
Oxford BioMedica PLC
Sector
Health Care
Country
United Kingdom
Funds holding it
2
Exposure themes
Gene Therapy, Genetic Medicine, Precision Medicine & Genomics

Funds holding Oxford BioMedica

Loading...